While trastuzumab seems to be effective only against breast cancer with amplified Her2 gene copy numbers and/or high Her2 surface expression, T-cells activated by tumor vaccines could potentially recognize tumors with intermediate or low levels of this molecule. The gene discussed is ERBB2; the disease is neoplasm.